QHMAC meeting outcomes-March 2014 - CATAG



MemorandumTo:HHS CEOsDirectors of Medical ServicesDirectors of PharmacyChairs, Medicines Advisory CommitteesCopies to:QHPIMS-Support UnitDispensary ManagersQHMAC MembersCentral Pharmacy (Graham Cook, Robin Lee, Nicole Zischke, Sam Webb)CIRCS (Maree Bransdon)From:Stephanie Boydell, Acting Executive Secretary Queensland Health Medicines Advisory CommitteeContact No:3131 6516Fax No: 3131 6568Subject:Summary of changes to the Queensland Health List of Approved Medicines (LAM) as a result of the March 2014 Queensland Health Medicines Advisory Committee (QHMAC) meetingFile Ref:CASS/0009421403advAt the March 2014 meeting the Queensland Health Medicines Advisory Committee (QHMAC) recommended the following changes to the List of Approved Medicines (LAM). These have been approved by the Committee Sponsor, Chief Executive, Health Services Support Agency (HSSA) and will be effective from 1 June 2014 - or as otherwise stated in the attached. There are six editions of the LAM each year. These current changes will be included in the 1 June 2014 edition of the LAM which will be published on QHEPS at . Please distribute this document as deemed appropriate to relevant clinicians. For future reference, monthly Summary of Changes can be found under “QHMAC meeting outcomes” at Note: These amendments may also include a number of items which are planned for earlier inclusion in the LAM – such as medicines which are available under the Highly Specialised Drugs Program or for which QHMAC specifically endorsed an earlier inclusion date.SignedStephanie BoydellActing Executive SecretaryQueensland Health Medicines Advisory Committee 02 / 05 / 2014March 2014 Summary of changes to the Queensland Health List of Approved Medicines (LAM) - recommended by the Queensland Health Medicines Advisory Committee (QHMAC)Item numberMedicineDecision and date effectiveRestriction14/018Chlorhexidine, alcoholic solution red 2% in alcohol 70%, 100mLAdded 01-Jun-1414/018AChlorhexidine, alcoholic solution pink 2% in alcohol 70%, 100mL Added 01-Jun-1414/014Denosumab injection, prefilled syringe 60mg in 1mLAdded 01-Jun-14For discharge and outpatient use as per the PBS indications. 14/007Fat emulsion - soya oil, MCT, olive oil, fish oil "SMOFlipid" IV infusion 20%, 100mLAdded 01-Jun-14 ‘Specialist Staff for use in neonates for prolonged intravenous therapy when oral or enteral feeding is not possible’14/010Ivabradine tablet 7.5mgAdded 01-Jun-14Specialist Staff for use in chronic heart failure, as per the PBS indications14/009APazopanib tablet 200mg, 400mgAdded01-Jun-14Specialist Staff for discharge and outpatient use in patients with stage IV clear cell renal cell carcinoma, as per the PBS indications13/103BEsomeprazole tablet 20mg (Pack of 7 only)Amended01-Jun-14Specialist Staff and Country Medical Superintendents for use in line with the proton pump inhibitor flowchart at Appendix 4.14/010Ivabradine tablet 5mgAmended01-Jun-14Cardiologists and Radiologists to reduce heart rate in patients in sinus rhythm undergoing CT coronary angiography who do not respond to maximal doses of betablockers or are unable to tolerate beta blockers (or when a beta blocker is contraindicated).Specialist Staff for use in chronic heart failure, as per the PBS indications13/103Omeprazole suspension 2mg per mL, 100mL Amended01-Jun-14Specialist Staff and Country Medical Superintendents for use in line with the proton pump inhibitor flowchart at Appendix 4. [Note: This restriction now includes use in neonates and infants, in addition to tube administration in patients up 18 years of age.]13/103AOmeprazole tablet (omeprazole magnesium) 10mg, 20mgAmended01-Jun-14Specialist Staff and Country Medical Superintendents for use in line with the proton pump inhibitor flowchart at Appendix 4.13/103CPantoprazole tablet 20mg, 40mgAmended01-Jun-14Specialist Staff and Country Medical Superintendents for use in line with the proton pump inhibitor flowchart at Appendix 4.14/016Alfentanil injection 1mg In 2mL Deferred14/015Hydromorphone hydrochloride injection 2mg in 1mLDeferred14/003Reactivated Item – Fondaparinux sodium injection pfs2.5mg in 0.5mLDeferredReviewing Individual Patient Approval (IPA) guideline for use in VTE prophylaxis. 14/008Vaccines for stem cell transplant recipients Deferred14/012Aprepitant, pack - 1 capsule 125mg and 2 capsules 80mg Deleted 01-Jan-1414/011A1Ganciclovir intravitreal implant 4.5mgDeleted 01-Jan-1414/017ARaloxifene tablet 60mgDeleted 01-Aug-1414/017Strontium ranelate sachet containing granules for oral suspension 2g (28) Deleted 01-Jun-1413/105Sodium chloride 0.9% prefilled syringe 10mL (BD Posiflush?)Not Added [Note: this item will be further considered at the May 2014 meeting.]13/102AAmphotericin: injection 50mg, lipid complexinjection 100mg in 20mL, liposomal injection 50mg Noted13/101ADalteparin sodium injection, prefilled syringe 2,500 IU in 0.2mL; 5,000 IU in 0.2mLNoted14/011A2Disodium pamidronate injection 15mg Noted13/103DOmeprazole capsule 20mgNoted14/013For information - review of the LAMNoted ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download